J. O'grady

发表

Autologous low-density lipoprotein labelling allows characterization of human atherosclerotic lesions in vivo as to presence of foam cells and endothelial coverage

P. Angelberger, H. Sinzinger, I. Virgolini, 2004, European Journal of Nuclear Medicine.

Prostaglandins and cardiovascular medicine

J. O'grady, S. Moody, 1987 .

Epoprostenol in patients with Raynaud's disease.

H. Sinzinger, P. Fitscha, J. Kaliman, 1988, Prostaglandins, leukotrienes, and essential fatty acids.

Low density lipoprotein labelling characterizes experimentally induced atherosclerotic lesions in rabbits in vivo as to presence of foam cells and endothelial coverage

P. Angelberger, H. Sinzinger, I. Virgolini, 2004, European Journal of Nuclear Medicine.

Accumulation of platelets as a key mechanism of human erection.

H. Sinzinger, J. O'grady, W. Stackl, 1998, Thrombosis research.

Accumulation of platelets as a key mechanism of human erection. A scintigraphic study in patients with erectile dysfunction receiving intracavernous injection of PGE1, papaverine/phentolamine.

H. Sinzinger, J. O'grady, W. Stackl, 1997, Advances in experimental medicine and biology.

Is a (n inborn) deficiency of prostacyclin synthesis stimulating plasma factor associated with increased lipoprotein(a)?

H. Sinzinger, J. O'grady, H. Kritz, 1996, Prostaglandins, leukotrienes, and essential fatty acids.

Eicosanoids in atherosclerosis.

A. Gazsó, H. Sinzinger, I. Virgolini, 1991, Experimental pathology.

A double blind placebo controlled crossover study of prostacyclin in man.

G. Fitzgerald, I. Miyamori, J. O'grady, 1979, Life sciences.

Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

J. O'grady, H. Pickles, 1982, British journal of clinical pharmacology.

Cigarette smoking does not attenuate the cardiovascular effects of epoprostenol (prostacyclin) in humans.

I. Macdougall, J. O'grady, H. Pickles, 1982, British journal of clinical pharmacology.

In vivo quantification of cholesterol content in human carotid arteries by quantitative gamma-camera imaging after injection of autologous low density lipoproteins (LDL).

P. Angelberger, H. Sinzinger, I. Virgolini, 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Isradipine lowers human arterial low density lipoprotein retention in vivo.

H. Sinzinger, P. Fitscha, J. O'grady, 1998, Prostaglandins, leukotrienes, and essential fatty acids.

Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis.

H. Sinzinger, J. O'grady, C. Pirich, 1996, Thrombosis research.

Prostaglandin E1 decreases human arterial accumulation of radiolabeled apo B-containing lipoproteins in vivo

H. Sinzinger, I. Virgolini, P. Fitscha, 1997, European Journal of Clinical Pharmacology.

Prostaglandin I2-mediated upregulation of 125I-LDL-receptor binding by isradipine in normo- and hypercholesterolemic rabbits in vivo.

H. Sinzinger, P. Fitscha, G. Lupattelli, 1996, Prostaglandins.

Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in man.

H. Sinzinger, P. Fitscha, F. Rauscha, 1992, British journal of clinical pharmacology.

Clinical pharmacology of prostacyclin

J. O'grady, P. Lewis, 1981 .

Noninvasive assessment of the cardiovascular effects of prostacyclin (PGI2) in man.

J. O'grady, P. R. Smith, S. Warrington, 1980, European journal of cardiology.

ASPIRIN: A PARADOXICAL EFFECT ON BLEEDING-TIME

S. Moncada, J. O'grady, 1978, The Lancet.

Hyperalphalipoproteinemia and prostaglandin I2 stability.

H. Sinzinger, J. O'grady, C. Pirich, 1997, Thrombosis research.

Effects of intravenous infusion of prostacyclin (PGI2) in man.

S. Moncada, R. Flower, J. O'grady, 1980, Prostaglandins.

Isradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production.

H. Sinzinger, P. Fitscha, J. O'grady, 1989, Thrombosis research.

Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivo.

H. Sinzinger, P. Fitscha, J. Kaliman, 1987, Prostaglandins.

Therapeutic Applications of Prostaglandins

J. Vane, J. O'grady, 1993 .

Isradipine inhibits mitotic and proliferative activity in the arterial wall.

H. Sinzinger, P. Fitscha, F. Rauscha, 1994, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

The prostacyclin stimulating plasma factor activity improves thromboresistance only if vascular PGI2-production is intact.

I. Neumann, H. Sinzinger, J. O'grady, 1996, Thrombosis research.

Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease

J. Vane, H. Sinzinger, P. Fitscha, 1990, The Lancet.

Prostacyclin infusion in hypertension: acute hemodynamic and hormonal effects.

J. O'grady, J. Cuche, M. Chaignon, 1982, The New England journal of medicine.

A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.

J. O'grady, Q. Mekki, A. Hedges, 1984, British journal of clinical pharmacology.

The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.

J. O'grady, H. Pickles, S. Warrington, 1982, British journal of clinical pharmacology.

Prolonged paradoxical effect of aspirin on platelet behaviour and bleeding time in man.

J. Salmon, S. Moncada, J. O'grady, 1979, Thrombosis research.

Comparable effect of prostaglandin E1 in decreasing in vivo platelet deposition on human lesion sites after intravenous and intraarterial application.

H. Sinzinger, P. Fitscha, J. Kaliman, 1988, Thrombosis research.

Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole

J. O'grady, H. Pickles, S. Warrington, 1983, Clinical pharmacology and therapeutics.

Beneficial effect of long-term PGE1-treatment in left ventricular heart failure.

H. Sinzinger, I. Virgolini, P. Fitscha, 1989, Prostaglandins, leukotrienes, and essential fatty acids.

Effect of a single oral dose of aspirin on the platelet aggregation response to arachidonic acid.

J. O'grady, A. Bye, Y. Lewis, 1979, British journal of clinical pharmacology.

Diminished platelet residence time on active human atherosclerotic lesions in-vivo--evidence for an optimal dose of aspirin?

H. Sinzinger, P. Fitscha, J. Kaliman, 1988, Prostaglandins, leukotrienes, and essential fatty acids.

The diminished extracellular matrix production induced by isradipine, a calcium channel blocker, is completely abolished by cyclooxygenase inhibition.

H. Sinzinger, P. Fitscha, F. Rauscha, 1992, Prostaglandins, Leukotrienes and Essential Fatty Acids.

Comparable Inhibitory Action of PGE1 and 13,14-dihydro-PGE1 on Smooth Muscle Cell Activity and Extracellular Matrix Production

I. Neumann, H. Sinzinger, P. Fitscha, 1991 .

Platelet Deposition on Human Atherosclerotic Lesions is Decreased by Low-Dose Aspirin in Combination with Dipyridamole

H. Sinzinger, P. Fitscha, J. O'grady, 1988, The Journal of international medical research.

Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease.

H. Sinzinger, I. Virgolini, P. Fitscha, 1992, Thrombosis research.

Clinical pharmacology in the pharmaceutical industry.

J. Vane, J. O'grady, 1991, British journal of clinical pharmacology.

Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance.

I. Neumann, H. Sinzinger, J. O'grady, 1998, Prostaglandins & other lipid mediators.

Methods of repeated venous sampling in man.

J. O'grady, A. Fowle, 1977, British journal of clinical pharmacology.

Apolipoprotein A and biological half-life of prostaglandin I2 in HIV-1 infection.

H. Sinzinger, J. O'grady, C. Pirich, 1996, Thrombosis research.

Effect of a hydantoin prostaglandin analogue, BW245C, during oral dosing in man.

J. O'grady, Q. Mekki, A. Hedges, 1985, Prostaglandins.

Continuous subcutaneous insulin-infusion pumps.

H. Sinzinger, P. Fitscha, J. Kaliman, 1984 .

PGE1-induced arterial thromboresistance is a vascular property as identified by cross-perfusion technique.

I. Neumann, H. Sinzinger, J. O'grady, 1997, Prostaglandins, leukotrienes, and essential fatty acids.

Isradipine decreases arterial thrombogenicity in rabbits. A morphometric and radioisotopic study.

H. Sinzinger, P. Fitscha, J. O'grady, 1994, Thrombosis research.

Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.

H. Sinzinger, J. O'grady, P. Schmid, 1999, Atherosclerosis.

Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.

W. Klepetko, P. Angelberger, H. Sinzinger, 1990, British Journal of Cancer.

Coffee, lipoproteins and cardiovascular disease.

H. Sinzinger, J. O'grady, C. Pirich, 1993, Wiener klinische Wochenschrift.

Defects in the prostaglandin-system--heredity, prevalence and vascular risk analysis.

H. Sinzinger, I. Virgolini, J. O'grady, 1990, Prostaglandins, leukotrienes, and essential fatty acids.

Changes in potential difference across the human buccal mucosa with buffered or unbuffered aspirin and salicylate.

J. O'grady, B. Whittle, K. Makki, 1981, Gut.

Effects of buffered aspirin and salicylate on the bio-electric potential difference across the human buccal mucosa [proceedings].

J. O'grady, B. Whittle, K. Makki, 1979, British journal of clinical pharmacology.

Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents.

J. O'grady, A. Hutt, 1996, The Journal of antimicrobial chemotherapy.

Effects of taprostene, a chemically stable prostacyclin analogue, in patients with ischaemic peripheral vascular disease: a placebo controlled double-blind trial.

H. Sinzinger, I. Virgolini, P. Fitscha, 1989, Prostaglandins, leukotrienes, and essential fatty acids.

The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide.

J. O'grady, B. Johnson, C. Bye, 1978, British journal of clinical pharmacology.

The comparative bioavailability of Lanoxin tablets and Lanoxicaps with and without sorbitol

J. O'grady, B. Johnson, C. Bye, 1978, European Journal of Clinical Pharmacology.

Influence of soft gelatin on digoxin absorption.

J. O'grady, B. Johnson, C. Bye, 1978, British journal of clinical pharmacology.

Hormonal Influences on Stress-Induced Neutrophil Mobilization in Health and Chronic Fatigue Syndrome

A. Komaroff, J. Cannon, J. O'grady, 1998, Journal of Clinical Immunology.

Effects of propranolol and oxprenolol on the vasoconstrictor response to noradrenaline in the superficial hand vein in man

J. O'grady, P. Turner, V. Oh, 1978, European Journal of Clinical Pharmacology.

Effect of prostacyclin (PGI2) on water and solute transport in the human jejunum.

J. O'grady, D. Rolston, M. Clark, 1986, Gut.

Effect of isradipine on in-vivo platelet function.

H. Sinzinger, J. O'grady, C. Pirich, 1997, Thrombosis research.

Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo.

H. Sinzinger, P. Fitscha, J. O'grady, 1987, Postgraduate medical journal.

Influence of a single dose of calcium channel blockers on platelet function.

H. Sinzinger, I. Virgolini, P. Fitscha, 1991, Platelets.

Using an interleukin-6 challenge to evaluate neuropsychological performance in chronic fatigue syndrome

D. Papanicolaou, J. Grafman, J. O'grady, 2002, Psychological Medicine.

DETECTION OF ANEURYSMS BY GAMMA-CAMERA IMAGING AFTER INJECTION OF AUTOLOGOUS LABELLED PLATELETS

H. Sinzinger, P. Fitscha, J. O'grady, 1984, The Lancet.

Influence of calcium antagonists on platelet function and vascular prostacyclin production.

H. Sinzinger, P. Fitscha, J. O'grady, 1994, Blood pressure. Supplement.

Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished.

H. Sinzinger, J. O'grady, H. Kritz, 1995, Thrombosis research.

13,14-dihydro-PGE1, an in-vivo metabolite of PGE1, decreases mitotic activity induced by corticosteroid administration.

H. Sinzinger, P. Fitscha, F. Rauscha, 1991, Eicosanoids.

Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease.

H. Sinzinger, I. Virgolini, J. O'grady, 1989, Progress in clinical and biological research.

[Clinical study of prostacyclin in extracorporeal circulation. Effects on hemodynamics and coagulation].

A. Carpentier, J. Vane, J. O'grady, 1982, Archives des maladies du coeur et des vaisseaux.

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems.

H Sinzinger, J O'Grady, H. Sinzinger, 2004, British journal of clinical pharmacology.

Enhanced in-vitro platelet aggregability during postprandial hyperlipidaemia

H. Sinzinger, P. Fitscha, J. O'grady, 1993, The Lancet.

Postprandial hyperlipemia does not inhibit platelet aggregation.

H. Sinzinger, P. Fitscha, J. O'grady, 1992, Prostaglandins, leukotrienes, and essential fatty acids.

Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold.

J. O'grady, D. Empey, D. Hughes, 1980, British medical journal.

Effect of a standard breakfast on digoxin absorption in normal subjects

J. O'grady, B. Johnson, C. Bye, 1978, Clinical pharmacology and therapeutics.

Platelet lipoxygenase defect (wien‐penzing defect) in two patients with myocardial infarction

H. Sinzinger, J. Kaliman, J. O'grady, 1991, American journal of hematology.

Aspirin abolishes the decreased low-density lipoprotein (LDL) entry into the rabbit arterial wall induced by the calcium channel blocker isradipine.

P. Angelberger, H. Sinzinger, I. Virgolini, 1992, Eicosanoids.

Naproxen in otitis media with effusion

J. O'grady, M. Mackinnon, S. Abramovich, 1986, The Journal of Laryngology & Otology.

Effect ofprostaglandin Elondeposition ofautologous labelled platelets ontohumanatherosclerotic lesions invivo

H. Sinzinger, J. O'grady, 1987 .

EPOPROSTENOL (PROSTACYCLIN) DECREASES PLATELET DEPOSITION ON VASCULAR PROSTHETIC GRAFTS

M. Cromwell, H. Sinzinger, J. O'grady, 1983, The Lancet.

EFFECT OF EPOPROSTENOL ON PLATELET DEPOSITION ON SYNTHETIC ARTERY GRAFTS

H. Sinzinger, P. Fitscha, J. Kaliman, 1984, The Lancet.

Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man.

H. Sinzinger, P. Fitscha, J. Kaliman, 1987, British journal of clinical pharmacology.

Isradipine improves platelet function in hypertensives

H. Sinzinger, I. Virgolini, P. Fitscha, 2004, European Journal of Clinical Pharmacology.

Alteration of rat cerebral microvascular eicosanoid formation by isradipine, a calcium channel blocker.

H. Sinzinger, J. O'grady, B. Peskar, 1998, Prostaglandins, leukotrienes, and essential fatty acids.

A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease.

H. Sinzinger, I. Virgolini, P. Fitscha, 1990, Prostaglandins.

Impaired conversion of exogenous arachidonic acid by platelets to thromboxane B2 and correction of that deficiency by interferon-alpha.

H. Gisslinger, H. Ludwig, H. Sinzinger, 1990, Prostaglandins.

99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) in vitro.

P. Angelberger, H. Sinzinger, I. Virgolini, 1990, British journal of clinical pharmacology.

Effects of single oral dose administration of a hydantoin prostaglandin analogue BW 245C in man.

A. Webster, J. O'grady, A. Shah, 1984, Life Science.

Impaired red blood cell deformability after oral administration of aspirin in man.

I. Kovács, J. O'grady, 1984, Biomedica biochimica acta.